{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T03:55:01Z","timestamp":1778903701449,"version":"3.51.4"},"reference-count":40,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2016,3,20]],"date-time":"2016-03-20T00:00:00Z","timestamp":1458432000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2016,3,30]],"date-time":"2016-03-30T00:00:00Z","timestamp":1459296000000},"content-version":"vor","delay-in-days":10,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"name":"Teva Branded Pharmaceutical Products R&D"},{"name":"Agile"},{"DOI":"10.13039\/100006483","name":"Abbvie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ContraMed"},{"name":"Evofem"},{"name":"HRA Pharma"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Teva Branded Pharmaceutical Products R&D"},{"name":"Agile"},{"DOI":"10.13039\/100006483","name":"AbbVie","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006483","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"name":"ContraMed"},{"name":"Evofem"},{"name":"HRA Pharma"},{"DOI":"10.13039\/100004334","name":"Merck","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ijgo.org","clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecology & Obstetrics"],"published-print":{"date-parts":[[2016,7]]},"DOI":"10.1016\/j.ijgo.2015.10.028","type":"journal-article","created":{"date-parts":[[2016,3,20]],"date-time":"2016-03-20T09:00:15Z","timestamp":1458464415000},"page":"8-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Rationale for eliminating the hormone-free interval in modern oral contraceptives"],"prefix":"10.1002","volume":"134","author":[{"given":"Andrew","family":"London","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey T.","family":"Jensen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2016,3,20]]},"reference":[{"issue":"(3)","key":"10.1016\/j.ijgo.2015.10.028-BIB0005|rf0005","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/j.contraception.2007.11.005","article-title":"Evaluation of pituitary-ovarian axis suppression with three oral contraceptive regimens","volume":"77","author":"Vandever","year":"2008","journal-title":"Contraception"},{"issue":"(6)","key":"10.1016\/j.ijgo.2015.10.028-BIB0010|rf0010","doi-asserted-by":"crossref","first-page":"1142","DOI":"10.1067\/mob.2002.122988","article-title":"Acceptance of altering the standard 21-day\/7-day oral contraceptive regimen to delay menses and reduce hormone withdrawal symptoms","volume":"186","author":"Sulak","year":"2002","journal-title":"Am J Obstet Gynecol"},{"issue":"(4)","key":"10.1016\/j.ijgo.2015.10.028-BIB0015|rf0015","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S0010-7824(99)00025-6","article-title":"Activity of the pituitary-ovarian axis in the pill-free interval during use of low-dose combined oral contraceptives","volume":"59","author":"van Heusden","year":"1999","journal-title":"Contraception"},{"issue":"(6 Suppl 1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0020|rf0020","first-page":"S1","article-title":"Progestin-only oral contraception: a comprehensive review","volume":"50","author":"McCann","year":"1994","journal-title":"Contraception"},{"key":"10.1016\/j.ijgo.2015.10.028-BIB0025|rf0025","first-page":"CD003989","article-title":"20 \u03bcg versus > 20 \u03bcg estrogen combined oral contraceptives for contraception","volume":"8","author":"Gallo","year":"2013","journal-title":"Cochrane Database Syst Rev"},{"issue":"(4)","key":"10.1016\/j.ijgo.2015.10.028-BIB0030|rf0030","doi-asserted-by":"crossref","first-page":"299","DOI":"10.3109\/09513599509160463","article-title":"The influence of the dose of ethinylestradiol in oral contraceptives on follicle growth","volume":"9","author":"Teichmann","year":"1995","journal-title":"Gynecol Endocrinol"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0035|rf0035","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.contraception.2007.09.010","article-title":"Effects on serum hormone levels of low-dose estrogen in place of placebo during the hormone-free interval of an oral contraceptive","volume":"77","author":"Reape","year":"2008","journal-title":"Contraception"},{"issue":"(5)","key":"10.1016\/j.ijgo.2015.10.028-BIB0040|rf0040","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.contraception.2004.05.006","article-title":"Ovarian follicular development is initiated during the hormone-free interval of oral contraceptive use","volume":"70","author":"Baerwald","year":"2004","journal-title":"Contraception"},{"issue":"(3)","key":"10.1016\/j.ijgo.2015.10.028-BIB0045|rf0045","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1095\/biolreprod.103.017772","article-title":"Characterization of ovarian follicular wave dynamics in women","volume":"69","author":"Baerwald","year":"2003","journal-title":"Biol Reprod"},{"issue":"(4)","key":"10.1016\/j.ijgo.2015.10.028-BIB0050|rf0050","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/humupd\/8.4.345","article-title":"Residual ovarian activity during oral steroid contraception","volume":"8","author":"van Heusden","year":"2002","journal-title":"Hum Reprod Update"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0055|rf0055","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.fertnstert.2005.12.046","article-title":"Effects of oral contraceptives administered at defined stages of ovarian follicular development","volume":"86","author":"Baerwald","year":"2006","journal-title":"Fertil Steril"},{"issue":"(5)","key":"10.1016\/j.ijgo.2015.10.028-BIB0060|rf0060","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.contraception.2014.06.033","article-title":"Correcting oral contraceptive pharmacokinetic alterations due to obesity: a randomized controlled trial","volume":"90","author":"Edelman","year":"2014","journal-title":"Contraception"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0065|rf0065","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1016\/j.contraception.2014.01.021","article-title":"Pituitary and ovarian hormone activity during the 7-day hormone-free interval of various combined oral contraceptive regimens","volume":"90","author":"Cho","year":"2014","journal-title":"Contraception"},{"issue":"(2)","key":"10.1016\/j.ijgo.2015.10.028-BIB0070|rf0070","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.contraception.2009.04.011","article-title":"Impact of obesity on oral contraceptive pharmacokinetics and hypothalamic-pituitary-ovarian activity","volume":"80","author":"Edelman","year":"2009","journal-title":"Contraception"},{"issue":"(3)","key":"10.1016\/j.ijgo.2015.10.028-BIB0075|rf0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/ejc.7.3.155.161","article-title":"Oral contraception: patterns of non-compliance. The Coraliance study","volume":"7","author":"Aubeny","year":"2002","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"(3)","key":"10.1016\/j.ijgo.2015.10.028-BIB0080|rf0080","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.contraception.2011.08.001","article-title":"Body weight does not impact pregnancy rates during use of a low-dose extended-regimen 91-day oral contraceptive","volume":"85","author":"Westhoff","year":"2012","journal-title":"Contraception"},{"issue":"(2)","key":"10.1016\/j.ijgo.2015.10.028-BIB0085|rf0085","first-page":"261","article-title":"Hormone withdrawal symptoms in oral contraceptive users","volume":"95","author":"Sulak","year":"2000","journal-title":"Obstet Gynecol"},{"issue":"(5)","key":"10.1016\/j.ijgo.2015.10.028-BIB0090|rf0090","doi-asserted-by":"crossref","first-page":"1311","DOI":"10.1016\/j.ajog.2006.05.012","article-title":"Oral contraceptives and premenstrual symptoms: comparison of a 21\/7 and extended regimen","volume":"195","author":"Coffee","year":"2006","journal-title":"Am J Obstet Gynecol"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0095|rf0095","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0010-7824(02)00445-6","article-title":"Bleeding patterns and patient acceptability of standard or continuous dosing regimens of a low-dose oral contraceptive: a randomized trial","volume":"67","author":"Kwiecien","year":"2003","journal-title":"Contraception"},{"issue":"(2)","key":"10.1016\/j.ijgo.2015.10.028-BIB0100|rf0100","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1080\/gye.17.2.107.114","article-title":"A meta-analysis on the correlation between ovarian activity and the incidence of intermenstrual bleeding during low-dose oral contraceptive use","volume":"17","author":"Endrikat","year":"2003","journal-title":"Gynecol Endocrinol"},{"issue":"(2)","key":"10.1016\/j.ijgo.2015.10.028-BIB0105|rf0105","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.contraception.2011.12.009","article-title":"Bleeding profile of a flexible extended regimen of ethinylestradiol\/drospirenone in US women: an open-label, three-arm, active-controlled, multicenter study","volume":"86","author":"Jensen","year":"2012","journal-title":"Contraception"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0110|rf0110","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/AOG.0b013e31820095a2","article-title":"Effectiveness of oral contraceptive pills in a large U.S. cohort comparing progestogen and regimen","volume":"117","author":"Dinger","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0115|rf0115","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.contraception.2013.09.007","article-title":"Comparison of pregnancy rates in users of extended and cyclic combined oral contraceptive (COC) regimens: a brief report","volume":"89","author":"Howard","year":"2014","journal-title":"Contraception"},{"issue":"(5)","key":"10.1016\/j.ijgo.2015.10.028-BIB0120|rf0120","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1016\/j.contraception.2013.12.006","article-title":"Comparison of rates of and charges from pregnancy complications in users of extended and cyclic combined oral contraceptive (COC) regimens: a brief report","volume":"89","author":"Howard","year":"2014","journal-title":"Contraception"},{"issue":"(4)","key":"10.1016\/j.ijgo.2015.10.028-BIB0125|rf0125","first-page":"699","article-title":"Economics of reducing menstruation with trimonthly-cycle oral contraceptive therapy: comparison with standard-cycle regimens","volume":"102","author":"Braunstein","year":"2003","journal-title":"Obstet Gynecol"},{"issue":"(3)","key":"10.1016\/j.ijgo.2015.10.028-BIB0130|rf0130","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.contraception.2004.05.013","article-title":"Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 micrograms ethinylestradiol and 3 mg drospirenone","volume":"70","author":"Bachmann","year":"2004","journal-title":"Contraception"},{"issue":"(2)","key":"10.1016\/j.ijgo.2015.10.028-BIB0135|rf0135","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0010-7824(01)00232-3","article-title":"Double-blind, multicenter comparison of efficacy, cycle control, and tolerability of a 23-day versus a 21-day low-dose oral contraceptive regimen containing 20 \u03bcg ethinyl estradiol and 75 \u03bcg gestodene","volume":"64","author":"Endrikat","year":"2001","journal-title":"Contraception"},{"key":"10.1016\/j.ijgo.2015.10.028-BIB0140|rf0140","first-page":"CD004695","article-title":"Continuous or extended cycle vs cyclic use of combined hormonal contraceptives for contraception","volume":"7","author":"Edelman","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"(5)","key":"10.1016\/j.ijgo.2015.10.028-BIB0145|rf0145","doi-asserted-by":"crossref","first-page":"321","DOI":"10.3109\/13625187.2014.927423","article-title":"Extended regimens of combined hormonal contraception to reduce symptoms related to withdrawal bleeding and the hormone-free interval: a systematic review of randomised and observational studies","volume":"19","author":"Mendoza","year":"2014","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"(4)","key":"10.1016\/j.ijgo.2015.10.028-BIB0150|rf0150","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ajog.2004.02.012","article-title":"Manipulation of the pill-free interval in oral contraceptive pill users: the effect on follicular suppression","volume":"190","author":"Schlaff","year":"2004","journal-title":"Am J Obstet Gynecol"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0155|rf0155","doi-asserted-by":"crossref","first-page":"S18","DOI":"10.1016\/S0002-9378(98)70292-3","article-title":"Ovarian activity in women taking an oral contraceptive containing 20 \u03bcg ethinyl estradiol and 150 \u03bcg desogestrel: effects of low estrogen doses during the hormone-free interval","volume":"179","author":"Killick","year":"1998","journal-title":"Am J Obstet Gynecol"},{"issue":"(6)","key":"10.1016\/j.ijgo.2015.10.028-BIB0160|rf0160","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/j.contraception.2015.03.001","article-title":"Ovulatory effects of three oral contraception regimens: a randomized, open-label, descriptive trial","volume":"91","author":"Seidman","year":"2015","journal-title":"Contraception"},{"issue":"(4)","key":"10.1016\/j.ijgo.2015.10.028-BIB0165|rf0165","doi-asserted-by":"crossref","first-page":"249","DOI":"10.3109\/13625187.2014.979282","article-title":"A phase 1, multicentre, open-label study to evaluate ovarian follicular activity and hormone levels with an extended-regimen combined oral contraceptive with low-dose ethinyl estradiol supplementation","volume":"20","author":"Kroll","year":"2015","journal-title":"Eur J Contracept Reprod Health Care"},{"issue":"(7)","key":"10.1016\/j.ijgo.2015.10.028-BIB0170|rf0170","doi-asserted-by":"crossref","first-page":"A543","DOI":"10.1016\/j.jval.2012.08.1915","article-title":"Comparison of unintended pregnancy rates among women who initiated oral contraceptive therapy with a 84\/7 estradiol or a 84\/7 placebo [abstract]","volume":"15","author":"Brewster","year":"2012","journal-title":"Value Health"},{"issue":"(2)","key":"10.1016\/j.ijgo.2015.10.028-BIB0175|rf0175","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/S0010-7824(03)00141-0","article-title":"A multicenter, randomized study of an extended cycle oral contraceptive","volume":"68","author":"Anderson","year":"2003","journal-title":"Contraception"},{"issue":"(5)","key":"10.1016\/j.ijgo.2015.10.028-BIB0180|rf0180","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.contraception.2008.11.011","article-title":"Adding low-dose estrogen to the hormone-free interval: impact on bleeding patterns in users of a 91-day extended regimen oral contraceptive","volume":"79","author":"Kaunitz","year":"2009","journal-title":"Contraception"},{"issue":"(1)","key":"10.1016\/j.ijgo.2015.10.028-BIB0185|rf0185","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.contraception.2004.07.013","article-title":"Endometrial microstructure after long-term use of a 91-day extended-cycle oral contraceptive regimen","volume":"71","author":"Anderson","year":"2005","journal-title":"Contraception"},{"issue":"(2)","key":"10.1016\/j.ijgo.2015.10.028-BIB0190|rf0190","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.contraception.2007.11.006","article-title":"Endometrial effects of a 91-day extended-regimen oral contraceptive with low-dose estrogen in place of placebo","volume":"77","author":"Anderson","year":"2008","journal-title":"Contraception"},{"issue":"(4)","key":"10.1016\/j.ijgo.2015.10.028-BIB0195|rf0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.contraception.2014.01.023","article-title":"Cardiovascular and general safety of a 24-day regimen of drospirenone-containing combined oral contraceptives: final results from the International Active Surveillance Study of Women Taking Oral Contraceptives","volume":"89","author":"Dinger","year":"2014","journal-title":"Contraception"},{"issue":"(5)","key":"10.1016\/j.ijgo.2015.10.028-BIB0200|rf0200","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.contraception.2006.12.019","article-title":"The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation","volume":"75","author":"Dinger","year":"2007","journal-title":"Contraception"}],"container-title":["International Journal of Gynecology & Obstetrics"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0020729216300406?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/api.elsevier.com\/content\/article\/PII:S0020729216300406?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2015.10.028","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1016%2Fj.ijgo.2015.10.028","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1016\/j.ijgo.2015.10.028\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,6,24]],"date-time":"2017-06-24T04:49:31Z","timestamp":1498279771000},"score":1,"resource":{"primary":{"URL":"http:\/\/doi.wiley.com\/10.1016\/j.ijgo.2015.10.028"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,3,20]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2016,7]]}},"URL":"https:\/\/doi.org\/10.1016\/j.ijgo.2015.10.028","archive":["Portico"],"relation":{},"ISSN":["0020-7292"],"issn-type":[{"value":"0020-7292","type":"print"}],"subject":[],"published":{"date-parts":[[2016,3,20]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Rationale for eliminating the hormone-free interval in modern oral contraceptives","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecology & Obstetrics","name":"journaltitle","label":"Journal Title"},{"value":"http:\/\/dx.doi.org\/10.1016\/j.ijgo.2015.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 International Federation of Gynecology and Obstetrics. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}